| Particulars (Rupees in Crores.) | Sept-2025 | Mar-2025 | Sept-2024 | Mar-2024 | Sept-2023 |
|---|---|---|---|---|---|
Gross Sales | 1,832.3 | 1,569.3 | 1,465.7 | 1,239.69 | 1,258.51 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,832.3 | 1,569.3 | 1,465.7 | 1,239.69 | 1,258.51 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.3 | 33.1 | 9.6 | 10.11 | 5.99 |
Total Income | 1,843.6 | 1,602.4 | 1,475.3 | 1,249.8 | 1,264.51 |
Total Expenditure | 1,436 | 1,184.1 | 1,068.2 | 937.1 | 924.2 |
PBIDT | 407.6 | 418.3 | 407.1 | 312.69 | 340.31 |
Interest | 77.6 | 52.4 | 37.8 | 28.76 | 18.24 |
PBDT | 330 | 365.9 | 369.3 | 283.93 | 322.07 |
Depreciation | 119.5 | 97.3 | 80 | 81.63 | 64.87 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 70.1 | 70.8 | 78.8 | 47.15 | 69.05 |
Deferred Tax | -16.6 | -0.8 | -5.4 | 7.22 | 0.18 |
Reported Profit After Tax | 157 | 198.6 | 215.9 | 147.94 | 187.97 |
Minority Interest After NP | 11.5 | 8.1 | 21.9 | 10.77 | 15.13 |
Net Profit after Minority Interest | 145.5 | 190.5 | 194 | 137.17 | 172.83 |
Extra-ordinary Items | -0.3 | 10.8 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 145.8 | 179.7 | 194 | 137.17 | 172.83 |
EPS (Unit Curr.) | 3.64 | 4.76 | 4.85 | 17.15 | 21.6 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 80 | 80 | 80 | 80 | 80.03 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 22.24 | 26.65 | 27.77 | 25.22 | 27.04 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 8.56 | 12.65 | 14.73 | 11.93 | 14.93 |
Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.
It has entered into a share purchase agreement to acquire a 100% equity stake in Chalasani Hospitals Pvt Ltd.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.